{"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}],"groups":[{"description":"Atezolizumab (1200 mg) intravenously administered every 21 days (one cycle) up to disease progression, unacceptable toxicity or absence of clinical benefit.\n\nGemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle plus Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles.\n\nAtezolizumab 1200 mg/m2: Fixed dose of 1200 mg/m2 by intravenous (IV) infusion on D1 of each cycle up to disease progression, unacceptable toxicity or absence of clinical benefit.\n\nGemcitabine 1000 mg/m2: Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle for up to 6 cycles.\n\nCisplatin 70 mg/m2: Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles.","id":"BG000","title":"AUREA Single-arm"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"49","upperLimit":"85","value":"71"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"57"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}],"title":"Spain"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}],"title":"Score 0"},{"measurements":[{"groupId":"BG000","value":"34"}],"title":"Score 1"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Score 2"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}]}],"description":"Scale validated by the World Health Organization (WHO) to assess the quality of life of cancer patients. The scale ranges from 0, patient fully active, to 5, patient dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group performance status (ECOG-PS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Upper tract"},{"measurements":[{"groupId":"BG000","value":"55"}],"title":"Lower tract"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}]}],"description":"Location of the primary tumor in the genitourinary tract: The upper tract was defined as the renal pelvis or ureter, and the lower tract as the bladder and urethra.","paramType":"COUNT_OF_PARTICIPANTS","title":"Site of the primary tumor","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Locally advanced"},{"measurements":[{"groupId":"BG000","value":"58"}],"title":"Metastatic"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}]}],"description":"Measures the extend of spread of the disease at the time of inclusion","paramType":"COUNT_OF_PARTICIPANTS","title":"Stage at inclusion","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44"}],"title":"Affected"},{"measurements":[{"groupId":"BG000","value":"22"}],"title":"Not affected"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}],"title":"Lymph nodes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}],"title":"Affected"},{"measurements":[{"groupId":"BG000","value":"30"}],"title":"Not affected"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}],"title":"Lung"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Affected"},{"measurements":[{"groupId":"BG000","value":"46"}],"title":"Not affected"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}],"title":"Bone"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Affected"},{"measurements":[{"groupId":"BG000","value":"54"}],"title":"Not affected"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}],"title":"Liver"}],"description":"Percentage of patients with organs affected by the disease. A patient may have more than 1 oragan affected","paramType":"COUNT_OF_PARTICIPANTS","title":"Metastatic locations","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"51"}],"title":"No"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}],"title":"ECOG 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"30"}],"title":"No"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}],"title":"Age > 70 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"33"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"33"}],"title":"No"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}],"title":"creatinine clearance 30-60 μmol/L"}],"description":"Criteria to consider patients not eligible for full doses of cisplatin. A patient may have more than one reason to be considered ineligible.","paramType":"COUNT_OF_PARTICIPANTS","title":"Reason unfit for full dose chemotherapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"No"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}],"title":"Surgery"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"57"}],"title":"No"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}],"title":"Radiotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior local therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Positive"},{"measurements":[{"groupId":"BG000","value":"26"}],"title":"Negative"},{"measurements":[{"groupId":"BG000","value":"26"}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"}],"units":"Participants"}]}],"description":"PD-L1, quantified using immunohistochemistry assays, is currently the most widely validated, used and accepted biomarker to guide the selection of patients to receive immunotherapy such as atezolizumab in this trial.\n\nPositivity indicates high expression of this biomarker and it has been shown to correlate with eficacy of immunotherapy in some tumor types. Negativity usually correlatess with worse prognosis to immunotherapy.\n\nThe prognostic value of PL-L1 in many cancer types is still under study.","paramType":"COUNT_OF_PARTICIPANTS","title":"PD-L1 status","unitOfMeasure":"Participants"}],"populationDescription":"Full Analysis Set"}